

# **Measuring effectiveness and impact of Japanese encephalitis vaccination**

**Immunization, Vaccines and Biologicals**



**World Health  
Organization**

---

**The Department of Immunization, Vaccines and Biologicals  
thanks the donors whose unspecified financial support  
has made the production of this document possible.**

This document was produced by the  
*Initiative for Vaccine Research (IVR)*  
of the Department of Immunization, Vaccines and Biologicals

*Ordering code: WHO/IVB/16.03*  
*Published: June 2016*

**This publication is available on the Internet at:**  
*<http://www.who.int/immunization/documents/en/>*

**Copies of this document as well as additional materials on  
immunization, vaccines and biologicals may be requested from:**

World Health Organization  
Department of Immunization, Vaccines and Biologicals  
CH-1211 Geneva 27, Switzerland

• Fax: + 41 22 791 4227 • Email: *[vaccines@who.int](mailto:vaccines@who.int)* •

© World Health Organization 2016

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: *[bookorders@who.int](mailto:bookorders@who.int)*). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: *[permissions@who.int](mailto:permissions@who.int)*).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

**Printed by the WHO Document Production Services, Geneva, Switzerland**

---

# **Measuring effectiveness and impact of Japanese encephalitis vaccination**

**Immunization, Vaccines and Biologicals**



**World Health  
Organization**



---

# 1. Contents

Acknowledgements.....	iii
Abbreviations & acronyms .....	iv
Preface .....	v
<b>1. Introduction .....</b>	<b>1</b>
1.1. Target audience and scope of the manual .....	2
1.2. Why are effectiveness and impact assessments necessary?.....	3
1.3. Epidemiology of Japanese encephalitis .....	5
1.4. Japanese encephalitis vaccines.....	6
1.5. How to approach JE vaccine assessment in the context of routine immunization and mass immunization campaigns .....	7
1.6. Summary and key points.....	9
<b>2. Measuring JE vaccine effectiveness .....</b>	<b>10</b>
2.1. Case-control studies .....	11
2.2. Case finding and identification.....	12
2.3. Choosing the location .....	13
2.4. Choosing the ages for inclusion .....	14
2.5. Informed consent .....	14
2.6. Vaccination status ascertainment.....	15
2.7. Minimizing bias and limitations.....	15
2.8. Data collection and management.....	16
2.9. Data analysis.....	17
2.10. Interpretation and extrapolation of results from vaccine effectiveness studies.....	17
2.11. Summary and key points.....	18
<b>3. Assessing vaccine impact by monitoring trends in disease     surveillance data .....</b>	<b>19</b>
3.1. Choosing the outcome.....	20
3.2. Recommended case definition .....	21
3.3. Choosing the location for an impact study .....	23
3.4. Choosing the ages for inclusion.....	23

---

---

3.5. Primary data sources .....	23
3.6. Secondary data sources.....	25
3.7. Data collection, analysis and reporting.....	25
3.8. Interpretation and extrapolation of results from vaccine impact studies .....	26
3.9. Case study .....	27
3.10. Summary and key points.....	27
<b>4. Conclusion .....</b>	<b>30</b>
References .....	31
Annex 1. Glossary of terms .....	34

---

# Acknowledgements

The points articulated in this document were based on discussion held during a WHO Expert Consultation on Measuring the Effectiveness and Impact of Japanese Encephalitis Vaccines, held 14–15 May 2015 in Geneva, Switzerland. This document was developed with the help of **Kirsten Vannice** (WHO) and **Karen Chang** (Johns Hopkins School of Public Health). Special thanks are due to the numerous colleagues who contributed to the preparation of this document by sharing updated information or by reviewing this document, including the following (in alphabetical order): **Nihal Abeyasinghe** (WHO SEARO), **Brad Biggerstaff** (US CDC), **James Heffelfinger** (WHO WPRO), **Susan Hills** (US CDC), **T Jacob John** (Christian Medical College), **Bill Letson** (PATH), **Stephen Luby** (Stanford University), **Tony Marfin** (PATH), **Florian Marks** (International Vaccine Institute), **Van Cuong Nguyen** (National Institute of Hygiene and Epidemiology, Viet Nam), **Peter Smith** (London School of Hygiene and Tropical Medicine), **Tom Solomon** (University of Liverpool), **Shyam Raj Upreti** (Ministry of Health and Population, Nepal).

---

# Abbreviations & acronyms

AES	Acute Encephalitis Syndrome
CDIBP	Chengdu Institute of Biological Products
CSF	cerebrospinal fluid
DALY	disability-adjusted life years
ELISA	enzyme-linked immunosorbent assay
EPI	Expanded Programme on Immunization
GMP	Good Manufacturing Practice
IRB	institutional review board
IRR	incidence rate ratio
JE	Japanese encephalitis
JEV	Japanese encephalitis virus
LP	lumbar puncture
OR	odds ratio
PIE	Post-Introduction Evaluation
RCT	randomized controlled trial
RR	relative risk
UNICEF	United Nations Children's Fund
VPD	vaccine-preventable disease

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27210](https://www.yunbaogao.cn/report/index/report?reportId=5_27210)

